Patents Represented by Attorney, Agent or Law Firm Arnold & Porter
  • Treatment of complement-associated disorders
    Patent number: 8088386
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: January 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8084200
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: December 27, 2011
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • Brilliant white cauliflower
    Patent number: 8084669
    Abstract: The present invention includes cauliflowers with enhanced whiteness and methods for obtaining such cauliflowers. The present invention also provides reagents that can be used in methods for obtaining such cauliflowers.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: December 27, 2011
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventors: Meinardus Petrus Boon, Franciscus Van Den Bosch, Gerard Koorevaar
  • Phosphorus-containing prodrugs
    Patent number: 8080536
    Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: December 20, 2011
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
  • Methods of treatment using antibodies to IL-17 homologous polypeptides
    Patent number: 8075888
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: December 13, 2011
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood
  • Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy
    Patent number: 8076066
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e.g., by fluorescent in situ hybridization.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: December 13, 2011
    Assignee: Genentech, Inc.
    Inventor: Robert D. Mass
  • Treatment with anti-ErbB2 antibodies
    Patent number: 8075892
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: December 13, 2011
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann
  • Method for making humanized antibodies
    Patent number: 8075890
    Abstract: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: December 13, 2011
    Assignee: Genentech, Inc.
    Inventors: Paul J. Carter, Leonard G. Presta
  • Primers and primer sets for use in methods to detect the presence of subsp.
    Patent number: 8071313
    Abstract: The present invention relates to oligonucleotide primers and primer sets that can be used to identify the bacterial pathogen Acidovorax avenae subsp. citrulli in a test sample.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: December 6, 2011
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventors: James Cucuzza, Carl Joseph Braun, III
  • Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
    Patent number: 8068990
    Abstract: The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns a comprehensive proteomic analysis of human amniotic fluid (AF) and cervical vaginal fluid (CVF), and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, pre-term labor, and/or chromosomal defects. The invention further concerns the identification of biomarkers and groups of biomarkers that can be used for non-invasive diagnosis of various pregnancy-related disorders, and diagnostic assays using such biomarkers.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: November 29, 2011
    Assignee: Hologic, Inc.
    Inventors: Ron Rosenfeld, Srinivasa Nagalla, Mike Gravett
  • PRO224 gene disruptions, and methods related thereto
    Patent number: 8067664
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: November 29, 2011
    Assignee: Genentech, Inc.
    Inventor: Wenhu Huang
  • Viral vectors and the use of the same for gene therapy
    Patent number: 8067227
    Abstract: The invention relates to viral vectors comprising nucleic acid sequences coding for single chain interleukin-12 (single chain IL-12 or scIL12) and a costimulator protein, and to the use of vectors for gene therapy, especially for the treatment of tumors. The invention further relates to adenoviral vectors containing nucleic acid sequences having a sequence homology of at least 90% in relation to the sequence displayed in FIGS. 19 and 20 (IL-12), in FIG. 21 (4-1BB ligand) and in FIG. 22 (IL-2) and optionally also one of the sequences displayed in FIG. 23A (B7-1) or 23B (B7-2).
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: November 29, 2011
    Assignee: Universitätsklinikum Hamburg-Eppendorf
    Inventors: Reinhard Wähler, Frank Schnieders
  • Nucleoside prodrugs and uses thereof
    Patent number: 8063025
    Abstract: Compounds having the formula I or II wherein R1, R2, B, and V are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: November 22, 2011
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Scott J. Hecker, K. Raja Reddy, Zhili Sun, Brett C. Bookser, David Bernard Smith
  • Assay methods and materials
    Patent number: 8062855
    Abstract: The invention relates to assays in which complexes between an analyte and a binding agent specific for the analyte are detected by a reporter molecule, which is capable of binding to the binding agent when the binding agent is complexed with analyte but not when the binding agent is complexed with an analyte analogue. The invention provides a method of modifying such a binding agent in order to create a tailored site where the reporter molecule may bind to the binding agent. This provides control over the location and nature of the reporter binding site. Antibodies, including bispecific antibodies, are preferred binding agents. The invention also provides novel methods for labelling antibodies close to their antigen binding site using bi- and tri-functional reagents. Modified binding agents produced by the methods described are also provided.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: November 22, 2011
    Assignee: Selective Antibodies Limited
    Inventor: Colin Henry Self
  • Antibodies to PRO7436 polypeptides
    Patent number: 8063186
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: November 22, 2011
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Protein purification
    Patent number: 8044017
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: October 25, 2011
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
    Patent number: 8034342
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: October 11, 2011
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • Broccoli type adapted for ease of harvest
    Patent number: 8030549
    Abstract: A broccoli plant characterized in having an exerted head having a crown higher than the leaf canopy and a harvestable head of at least about 200 grams when planted at a density of 40,000 plants per hectare, where the harvestable head comprises the top 25 centimeters of said stalk.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: October 4, 2011
    Assignee: Seminis Vegetable Seeds, Inc.
    Inventors: Franciscus van den Bosch, Meindert P. Boon
  • Nucleic acid encoding DR5 antibodies and uses thereof
    Patent number: 8030023
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • DR5 antibodies and articles of manufacture containing same
    Patent number: 8029783
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi